Setara Life Sciences Fund LP
Raised
Pre-open
Investors
—
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
Setara Life Sciences Fund LP is a Delaware limited partnership filing under Rule 506(b) and Section 3(c)(1), managed by Setara Capital Management LLC. This is a pre-open filing with no capital raised, investor count, or minimum investment disclosed. The fund targets longevity biotech investments and operates as a pooled investment vehicle.
This longevity biotech fund follows a standard institutional structure using 506(b) exemption paired with 3(c)(1) investor limits, typical for private biotech funds seeking fewer than 100 accredited investors. The pre-open filing provides no investment threshold or raise target, consistent with early-stage fund formation disclosures in this category.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
- Setara Capital Management LLC
Executive Officer, Promoter · NEW YORK, NY
- Setara Capital GP LLC
Executive Officer, Promoter · NEW YORK, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.